Dyax Corp. and Five Prime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies

27-Apr-2011 - USA

Dyax Corp. and Five Prime Therapeutics, Inc. announced that they have entered into an antibody funded research agreement for the discovery of therapeutic antibodies.

Under the terms of this agreement, Dyax will utilize its proprietary "gold-standard" phage display technology to identify therapeutic antibodies for multiple targets from FivePrime, with an option to expand the scope of the collaboration to include additional targets. Dyax will receive technology license fees and full-time employee payments from FivePrime for the funded research as well as clinical and sales milestone payments and royalties on net sales that may result from FivePrime's development and commercialization of antibodies from Dyax's libraries.

"This collaboration holds tremendous potential given the clear fit between Dyax's phage display technology, which enables the rapid identification of drug candidates to targets of therapeutic interest, and the technology FivePrime employs to identify medically relevant antibody targets," commented Gustav A. Christensen, President and CEO of Dyax Corp. "Our Licensing and Funded Research Program is a franchise which continues to deliver significant value both in the near-term, through collaborations like the one announced today, and long-term, through its portfolio of 17 clinical product candidates including eight in late-stage clinical trials."

"We believe that the combination of FivePrime's unique engine for the discovery of innovative biologics with the proven phage display technology of Dyax will generate important human antibodies to modulate FivePrime's proprietary targets," stated Julia P. Gregory, President and CEO of FivePrime. "FivePrime is focused on the innovation of protein and antibody drugs. Dyax's expertise in antibody therapeutic discovery accelerates these efforts, allowing us to expand our growing pipeline of product candidates."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous